Bifogade filer
Dicot Pharma Invites to a live company presentation and Q&A session in Swedish on May 27
Kurs
-0,38%
Likviditet
2,30 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2027-02-12 | 08:00 | Bokslutskommuniké 2026 |
| 2026-10-28 | 08:00 | Kvartalsrapport 2026-Q3 |
| 2026-08-20 | 08:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-07 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2026-05-06 | - | Årsstämma |
| 2026-04-30 | - | Kvartalsrapport 2026-Q1 |
| 2026-02-18 | - | Bokslutskommuniké 2025 |
| 2025-10-23 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-12 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2025-05-06 | - | Årsstämma |
| 2025-04-29 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-08-01 | - | Extra Bolagsstämma 2024 |
| 2024-05-07 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2024-05-06 | - | Årsstämma |
| 2024-05-06 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-26 | - | Bokslutskommuniké 2023 |
| 2023-10-31 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-24 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2023-05-23 | - | Årsstämma |
| 2023-05-19 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-27 | - | Bokslutskommuniké 2022 |
| 2023-01-09 | - | Extra Bolagsstämma 2022 |
| 2022-11-01 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-06 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-28 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-10-06 | - | Extra Bolagsstämma 2021 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-26 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2021-05-25 | - | Årsstämma |
| 2021-05-17 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-24 | - | Bokslutskommuniké 2020 |
| 2020-11-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-15 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-28 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Extra Bolagsstämma 2019 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-17 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Uppsala, Sweden, May 22, 2026. Dicot Pharma invites shareholders and other investors to a live company presentation and Q&A session in connection with the company’s ongoing rights offering. The company will present its plans for phase 2b, upcoming milestones, and how to participate in the offering. The presentation will take place via Zoom on May 27 at 12:00 p.m. CEST.
The presentation is open to everyone. To register to attend, please go to https://us02web.zoom.us/webinar/register/WN_mqkLMrccTBOpP9oFIQdvBA. If you can’t make it at the scheduled time, you’ll be able to watch the presentation later.
Please feel free to send any questions you may have before the presentation to info@dicotpharma.com.
The broadcast will be moderated by Alexander Kangas from Corpura, and participants from the company will include CEO Elin Trampe and CFO Björn Petersson. Note that the presentation will be in Swedish.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma’s business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.
Dicot Pharma is listed on Nasdaq First North and has approximately 16,750 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.
This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.